StockNews.com began coverage on shares of ARCA biopharma (NASDAQ:ABIO – Free Report) in a report published on Sunday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.
ARCA biopharma Trading Up 1.7 %
Shares of ARCA biopharma stock opened at $3.49 on Friday. The firm has a fifty day simple moving average of $2.30 and a 200-day simple moving average of $1.95. The stock has a market capitalization of $50.64 million, a price-to-earnings ratio of -8.29 and a beta of 1.17. ARCA biopharma has a 1-year low of $1.56 and a 1-year high of $3.88.
ARCA biopharma (NASDAQ:ABIO – Get Free Report) last announced its earnings results on Thursday, February 1st. The biopharmaceutical company reported ($0.08) EPS for the quarter.
Institutional Investors Weigh In On ARCA biopharma
ARCA biopharma Company Profile
ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.
Read More
- Five stocks we like better than ARCA biopharma
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- How to Calculate Stock Profit
- Hilton Demonstrates Asset Light is Right for Investors
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for ARCA biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARCA biopharma and related companies with MarketBeat.com's FREE daily email newsletter.